A series of 25 chiral anti-cancer
lipidic alkynylcarbinols
(LACs)
were devised by introducing an (hetero)aromatic ring between the aliphatic
chain and the dialkynylcarbinol warhead. The resulting phenyl-dialkynylcarbinols
(PACs) exhibit enhanced stability, while retaining cytotoxicity against
HCT116 and U2OS cell lines with IC50 down to 40 nM for
resolved eutomers. A clickable probe was used to confirm the PAC prodrug
behavior: upon enantiospecific bio-oxidation of the carbinol by the
HSD17B11 short-chain dehydrogenase/reductase (SDR), the resulting
ynones covalently modify cellular proteins, leading to endoplasmic
reticulum stress, ubiquitin–proteasome system inhibition, and
apoptosis. Insights into the design of LAC prodrugs specifically bioactivated
by HSD17B11 vs its paralogue HSD17B13 were obtained. The HSD17B11/HSD17B13-dependent
cytotoxicity of PACs was exploited to develop a cellular assay to
identify specific inhibitors of these enzymes. A docking study was
performed with the HSD17B11 AlphaFold model, providing a molecular
basis of the SDR substrates mimicry by PACs. The safety profile of
a representative PAC was established in mice.